Advertisement
Ardelyx Inc (41X.SG)
Stuttgart - Stuttgart Delayed Price. Currency in EUR
Follow
At close: 09:32PM CET
| Previous Close | 5.97 |
| Open | 5.88 |
| Bid | 5.92 x 0 |
| Ask | 5.97 x 0 |
| Day's Range | 5.78 - 5.94 |
| 52 Week Range | 3.23 - 9.46 |
| Volume | |
| Avg. Volume | 53 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Oct 31, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireArdelyx to Participate at the 2024 Jefferies London Healthcare Conference
WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, Justin Renz, Chief Financial and Operations Officer and Eric Foster, Chief Commercial Officer, will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, No
Simply Wall St.Ardelyx Third Quarter 2024 Earnings: US$0.003 loss per share (vs US$0.03 profit in 3Q 2023)
Ardelyx ( NASDAQ:ARDX ) Third Quarter 2024 Results Key Financial Results Revenue: US$98.2m (up 74% from 3Q 2023). Net...
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.